Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial-Reference-Cited by-同舟云学术

Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial

Published:2023-01 Issue:1 Volume:10 Page:e15-e23
ISSN:2352-3018
Container-title:The Lancet HIV
language:en
Short-container-title:The Lancet HIV

Author:

Gupta Samir K,Berhe Mezgebe,Crofoot Gordon,Benson Paul,Ramgopal Moti,Sims James,McDonald Cheryl,Ruane Peter,Sanchez William E,Scribner Anita,Liu Shan-Yu,VanderVeen Laurie A,Dvory-Sobol Hadas,Rhee Martin S,Baeten Jared M,Koenig Ellen

Funder

Gilead Sciences

Publisher

Elsevier BV

Subject

Virology,Infectious Diseases,Immunology,Epidemiology

Reference18 articles.

1. Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta-analysis;Teeraananchai;HIV Med,2017

2. Antiretroviral therapy for the prevention of HIV-1 transmission;Cohen;N Engl J Med,2016

3. A systematic review of treatment fatigue among HIV-infected patients prescribed antiretroviral therapy;Claborn;Psychol Health Med,2015

4. Patient-reported barriers to adherence to antiretroviral therapy: a systematic review and meta-analysis;Shubber;PLoS Med,2016

5. Structural and mechanistic bases for a potent HIV-1 capsid inhibitor;Bester;Science,2020

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring HIV-1 Maturation: A New Frontier in Antiviral Development;Viruses;2024-09-06

2. Lenacapavir to prevent HIV infection: current prices versus estimated costs of production;Journal of Antimicrobial Chemotherapy;2024-09-03

3. The Current Pipeline of Antiretroviral Therapy;Infectious Disease Clinics of North America;2024-09

4. Aging on antiretrovirals: reviewing the need for pharmacologic data in elderly people with HIV;AIDS;2024-07-02

5. Consensus recommendations for use of long‐acting antiretroviral medications in the treatment and prevention of HIV‐1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy, Canadian HIV and Viral Hepatitis Pharmacists Network, European AIDS Clinical Society, and Society of Infectious Diseases Pharmacists;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-07